NextCure
NXTC
30 hedge funds and large institutions have $2.78M invested in NextCure in 2026 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 7 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
15% more funds holding
Funds holding: 26 → 30 (+4)
12.9% less ownership
Funds ownership: 60.93% → 48.04% (-13%)
88% less capital invested
Capital invested by funds: $23M → $2.78M (-$20.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.05M |
| 2 |
Renaissance Technologies
New York
|
+$818K |
| 3 |
Millennium Management
New York
|
+$651K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$370K |
| 5 |
HF
HRT Financial
New York
|
+$269K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.88M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.51M |
| 3 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
-$1.48M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$1.48M |
| 5 |
AIC
AWM Investment Company
New York
|
-$1.23M |
NXTC Hedge Fund Activity: Q2 2026 in Review
30 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q2 2026, worth a combined $2.78M — down 88% from $23M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new NXTC positions and 7 closed out — a net gain of 4 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $2.05M. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $1.88M sold.
- 30 institutional investors held NextCure (NXTC) as of Q2 2026, up from 26 in Q1 2026.
- Funds reported $2.78M of NextCure stock for Q2 2026, down 88% quarter-over-quarter.
- 11 funds opened new NextCure positions in Q2 2026 and 7 closed out, a net change of +4 holders.
- The largest NextCure buyer in Q2 2026 was Adage Capital Partners, an estimated $2.05M added.
- The largest NextCure seller in Q2 2026 was Silverarc Capital Management, an estimated $1.88M sold.
Based on aggregated 13F filings for Q2 2026.